Source comparison
Comparison: AOD-9604 Dosing Protocols Across Research Contexts
Pre-clinical rodent models (Monash University, 2001) 500mcg/kg body weight Once daily, subcutaneous 14 days 50% reduction in epididymal fat pad mass vs vehicle control Dose not directly translatable to humans due to metabolic rate scaling. Human equivalent dos
This comparison does not assign a generated winner or score.
- Pre-clinical rodent models (Monash University, 2001)
- 500mcg/kg body weight
- Once daily, subcutaneous
- 14 days
- 50% reduction in epididymal fat pad mass vs vehicle control
- Dose not directly translatable to humans due to metabolic rate scaling. Human equivalent dose approximately 80mcg/kg or 5.6mg for 70kg adult
- Phase 1 human safety trial (2004)
- 1mg total dose
- Single administration
- Acute (24-hour observation)
- Peak plasma concentration 8.2ng/mL at 45 minutes; no adverse glycemic effects
- Established safety and PK profile. Terminal half-life 2.5 hours supports once-daily dosing
- Phase 2b OPAL trial (obese adults, 2008)
- 1mg
- 12 weeks
- No significant difference in body weight vs placebo; DEXA showed −2.6% subcutaneous fat in responder subset
- Suggests either dose insufficient to overcome individual variability or beta-3 receptor downregulation with chronic administration
- Investigational research protocols (contemporary, 2026)
- 300–500mcg
- Once daily, fasted state
- 8–12 weeks
- Variable. Depot-specific fat loss in 30–40% of subjects based on beta-3 receptor polymorphisms
- Responder phenotype likely tied to Trp64Arg polymorphism in ADRB3 gene; non-responders show minimal effect regardless of dose